Jazz Pharmaceuticals plc
JAZZ
NASDAQ·Healthcare·Biotechnology·Mkt cap $15.3B
$245.57
▲ +0.76%
P/E
16.16
Mkt Cap
$15.3B
52-Wk Range
$123.88–$266.38
52-Week Range
$123.88 - $266.38
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 88.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Specialized expertise in orphan and rare diseases with limited competition
- Established market leadership in narcolepsy treatment with Xyrem and Xywav
- Diversified pipeline with multiple late-stage candidates reducing portfolio risk
- Strategic partnerships with biotech innovators enhancing R&D capabilities
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
Launch and expansion of next-generation products like Xywav and JZP-324
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+7.8% over 3m
Quality
Excellent
Exceptional business - top-tier fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying JAZZ right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 3, 2026
Reported EPS of $5.71 vs $6.18 consensus (-7.6% surprise). Revenue of $1.2B vs $1.1B expected (+8.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-7.6%
Revenue trend · last 8Q
—
—
-0%
+2%
+7%
+10%
+19%
+16%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$1.1B
$1.1B
$897.8M
$1.0B
$1.1B
$1.2B
$1.1B
$1.2B
Margins · last 8Q
Gross
0.0%
Operating
20.5%
Profit
16.0%
Wall Street consensus
12 analysts · 92% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
92%
Hold
8%
Sell
0%
Median Price Target
—
Latest: Morgan Stanley · Aug 26, 2026
vs Industry
How JAZZ stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.